Literature DB >> 19120132

GABA regulates the rat hypothalamic-pituitary-adrenocortical axis via different GABA-A receptor alpha-subtypes.

Jens D Mikkelsen1, Jana Bundzikova, Marianne H Larsen, Henrik H Hansen, Alexander Kiss.   

Abstract

The control of the corticotropin-releasing hormone (CRH) neurons in the hypothalamic paraventricular nucleus (PVN) is balanced by excitatory and inhibitory inputs. The GABA-A receptor, which is a major target for the inhibitory control, is composed of five subunits. The presence of an alpha(1)-, alpha(2)-, alpha(3)-, or alpha(5)-subunit in the GABA-A receptor protein complex is necessary for benzodiazepines to exert their potentiating effect on the receptor. We postulate that the effect of nonselective benzodiazepines on the hypothalamo-pituitary adrenocortical (HPA) axis is critically dependent on the composition of the GABA-A receptor subunits through which they act. We show here that positive modulators of alpha(1)-subtype containing GABA-A receptors with zolpidem (10 mg/kg) increase HPA activity in terms of increase in plasma corticosterone and induction of Fos in the PVN, whereas activation of non-alpha(1)-subtype GABA-A receptors using L-818,417 (10 mg/kg) likely inhibits the activity. We also show that the alpha(2)-subunit gene is highly expressed in the PVN, but its expression is not affected by chronic mild stress. These results show that the stimulatory effect on HPA activity after positive modulation of GABA-A receptors composed of alpha(1)-subunit(s) affects a selective afferent system than the PVN, which is distinct from another afferent system(s) activated by non alpha(1)-containing GABA-A receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19120132     DOI: 10.1196/annals.1410.044

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  4 in total

1.  Dysfunctional neurotransmitter systems in fibromyalgia, their role in central stress circuitry and pharmacological actions on these systems.

Authors:  Susanne Becker; Petra Schweinhardt
Journal:  Pain Res Treat       Date:  2011-10-02

2.  Effects of trazodone versus cognitive behavioral therapy in the insomnia with short sleep duration phenotype: a preliminary study.

Authors:  Alexandros N Vgontzas; Kristina Puzino; Julio Fernandez-Mendoza; Venkatesh Basappa Krishnamurthy; Maria Basta; Edward O Bixler
Journal:  J Clin Sleep Med       Date:  2020-12-15       Impact factor: 4.062

3.  Alterations in brain-derived neurotrophic factor in the mouse hippocampus following acute but not repeated benzodiazepine treatment.

Authors:  Stephanie C Licata; Nina M Shinday; Megan N Huizenga; Shayna B Darnell; Gavin R Sangrey; Uwe Rudolph; James K Rowlett; Ghazaleh Sadri-Vakili
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

4.  Risk of Type 2 Diabetes in Patients With Nonapnea Sleep Disorders in Using Different Types of Hypnotics: A Population-Based Retrospective Cohort Study.

Authors:  Chia-Ling Lin; Mei-Chang Yeh; Tomor Harnod; Cheng-Li Lin; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.